|
WO2021081062A1
|
|
Methods and compositions for treating liver diseases and disorders
|
|
WO2020247625A1
|
|
Formulations and doses of pegylated uricase
|
|
US2020390718A1
|
|
Methods and compositions for attenuated anti-viral transfer vector immune response
|
|
WO2020223205A1
|
|
Methods for treatment of subjects with preexisting immunity to viral transfer vectors
|
|
WO2020018587A1
|
|
Methods and compositions of mma constructs and vectors
|
|
KR20210032438A
|
|
Methods and compositions of OTC constructs and vectors
|
|
CN111542336A
|
|
Methods and compositions for attenuating antiviral transfer vector IGM response
|
|
KR20190124295A
|
|
Methods and compositions related to combination treatment with synthetic nanocarriers comprising anti-inflammatory agents and immunosuppressants
|
|
WO2018129268A1
|
|
Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
|
|
EP3518956A1
|
|
Recombinant immunotoxins for use in the treatment of cancer
|
|
US2018071394A1
|
|
Polyester polymer matrices for the delivery of allergens
|
|
EP3426285A1
|
|
Formulations and doses of pegylated uricase
|
|
US2016128987A1
|
|
Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
|
|
WO2016037165A1
|
|
Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
|
|
US2015374815A1
|
|
Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
|
|
US2015359865A1
|
|
Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
|
|
US2016220501A1
|
|
Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
|
|
KR20160015293A
|
|
Repeated administration of non-immunosupressive antigen specific immunotherapeutics
|
|
AU2014262164A1
|
|
Dosing combinations for reducing undesired humoral immune responses
|
|
AU2014262165A1
|
|
Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
|
